molsidomine has been researched along with Fibrosis in 4 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
Excerpt | Relevance | Reference |
---|---|---|
" We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican-null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies." | 7.79 | The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. ( Brunelli, S; Campana, L; Clementi, E; Cottone, L; Querini, PR; Sciorati, C; Zordan, P, 2013) |
"NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis." | 7.72 | NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. ( Daig, U; Krämer, S; Liefeldt, L; Martini, S; Neumayer, HH; Peters, H; Rückert, M; Schäper, F, 2003) |
"Thus, in our model of chronic renocardiac syndrome, combined treatments similarly decreased cardiac fibrosis and stabilized systolic function as losartan alone, perhaps suggesting a dominant role for a single factor such as angiotensin II type 1 (AT1) receptor activation or inflammation in the network of aberrant systems in the heart." | 3.85 | Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation. ( Bongartz, LG; Braam, B; Cheng, C; Cramer, MJ; Doevendans, PA; Gaillard, CA; Goldschmeding, R; Joles, JA; Oosterhuis, NR; van Koppen, A; Verhaar, MC; Xu, YJ, 2017) |
" We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican-null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies." | 3.79 | The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. ( Brunelli, S; Campana, L; Clementi, E; Cottone, L; Querini, PR; Sciorati, C; Zordan, P, 2013) |
"• To investigate whether sustained long-term separate treatments of diabetic inducible nitric oxide synthase knockout (iNOSKo) mice with allopurinol, an antioxidant inhibiting xanthine oxidoreductase, decorin, a transforming growth factor-β1 (TGFβ1) -binding antagonist, and molsidomine, a long-life nitric oxide donor, prevent the processes of diabetes-induced cavernosal fibrosis." | 3.78 | Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice. ( Ferrini, MG; Gonzalez-Cadavid, NF; Moon, J; Rajfer, J; Rivera, S, 2012) |
"NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis." | 3.72 | NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. ( Daig, U; Krämer, S; Liefeldt, L; Martini, S; Neumayer, HH; Peters, H; Rückert, M; Schäper, F, 2003) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Zordan, P | 1 |
Sciorati, C | 1 |
Campana, L | 1 |
Cottone, L | 1 |
Clementi, E | 1 |
Querini, PR | 1 |
Brunelli, S | 1 |
Oosterhuis, NR | 1 |
Bongartz, LG | 1 |
Verhaar, MC | 1 |
Cheng, C | 1 |
Xu, YJ | 1 |
van Koppen, A | 1 |
Cramer, MJ | 1 |
Goldschmeding, R | 1 |
Gaillard, CA | 1 |
Doevendans, PA | 1 |
Braam, B | 1 |
Joles, JA | 1 |
Ferrini, MG | 1 |
Moon, J | 1 |
Rivera, S | 1 |
Rajfer, J | 1 |
Gonzalez-Cadavid, NF | 1 |
Peters, H | 1 |
Daig, U | 1 |
Martini, S | 1 |
Rückert, M | 1 |
Schäper, F | 1 |
Liefeldt, L | 1 |
Krämer, S | 1 |
Neumayer, HH | 1 |
4 other studies available for molsidomine and Fibrosis
Article | Year |
---|---|
The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy.
Topics: Animals; Disease Models, Animal; Fibrosis; Humans; Immunity, Innate; Inflammation; Mice; Molsidomine | 2013 |
Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cardio-Renal Syndrome; Coronary Vess | 2017 |
Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice.
Topics: Allopurinol; Animals; Antioxidants; Apoptosis; Decorin; Diabetes Mellitus, Experimental; Enzyme Inhi | 2012 |
NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis.
Topics: Animals; Arginine; Blood Pressure; Body Weight; Enzyme Inhibitors; Fibronectins; Fibrosis; Gene Expr | 2003 |